Access Pharmaceuticals, Inc., a biopharmaceutical company,

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2013 at 6:30 PM

Access Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing a range of pharmaceutical and medical device products primarily based upon nanopolymer chemistry technologies and other drug delivery technologies. Products MuGard: MuGard is a marketed product for the management of oral mucositis, a frequent side-effect of cancer therapy. MuGard, a proprietary nanopolymer formulation, has received marketing allowance in the U.S. from the U.S. Food and Drug Administration (FDA). The company launched MuGard in the United States in 2010. MuGard has also been launched in Germany, Italy, the United Kingdom, Greece and the Nordic countries by the company’s European commercial partner, SpePharm. In March 2012, the company’s partner, Rhei Pharmaceuticals HK LTtd., received regulatory and marketing approval for MuGard from the State Food and Drug Administration to treat oral mucositis in cancer patients. ProLindac: The company’s development candidate for the treatment of cancer is ProLindac, a nanopolymer DACH (Diamino Cyclohexane)-platinum prodrug. It initiated a study of ProLindac combined with Paclitaxel in second line treatment of platinum pretreated advanced ovarian cancer patients in 2010. This multi-center study of up to 25 evaluable patients is being conducted in France. A second combination study was initiated in 2011 combining ProLindac with gemcitabine for the treatment of cholangiocarcinoma. Clinical studies of other indications, including liver, colorectal, and ovarian cancer are under consideration by Jiangsu Aosaikang Pharmaceutical Co., Ltd, the company’s licensee for ProLindac in China. Thiarabine: Thiarabine, or 4-thio Ara-C, is a nucleoside analog licensed from Southern Research Institute. The company is in the process of working with leukemia and lymphoma specialists at MD Anderson Cancer Center in Houston and has initiated additional Phase 2 clinical trials in adult AML, ALL and other indications. CobOral: CobOral is the company’s proprietary preclinical nanopolymer oral drug delivery technology based on the natural vitamin B12 oral uptake mechanism. The company is in the process of developing a product for the oral delivery of insulin, and has conducted sponsored development of a product for oral delivery of peptides and RNAi therapeutics. CobaCyte: CobaCyte-mediated targeted delivery is a preclinical technology which makes use of the fact that cell surface receptors for vitamins, such as B12 are often overexpressed by certain cells including many cancers. This technology uses nanopolymer constructs to deliver more anti-cancer drug to tumors while protecting normal tissues. Patents For mucoadhesive liquid technology, two U.S. patents have issued, one European patent has been granted and one European patent application is under review. The European patent has issued in 19 European countries. Five U.S. patents and two European patents were issued and two European patent applications are pending for polymer platinum compounds. The patents and patent applications are the result in part of collaboration with The School of Pharmacy, University of London, from which the technology has been licensed and include a synthetic polymer, hydroxypropylmethacrylamide incorporating platinates, that can be used to exploit enhanced permeability and retention in tumors and control drug release. Thiarabine is subject to two process patents that expire in 2018, one use patent that expires in 2019, as well an additional patent which expires in 2027. Regulation The company is subject to regulation by the federal government, principally by the FDA, and by other federal and state agencies as well as comparable agencies in foreign countries where registration of products would be pursued. The Federal Food, Drug and Cosmetic Act and other federal, state and foreign statutes and regulations govern the testing, manufacturing, safety, labeling, storage, shipping and record keeping of the company’s products. Competition Thiarabine’s competitors are Eli Lilly and Company, Bayer Healthcare, Cyclacel, Ltd., SciClone Pharmaceuticals and Genzyme. History Access Pharmaceuticals, Inc. was founded in 1988.

Abeona Therapeutics Inc. (ABEO) Stock Research Links

ABEO Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OneAscent Welcomes Monica Stoudemire as New CCO

New Leadership in Compliance Diving straight into the tumultuous sea of securities compliance, OneAscent's got a fresh captain at the helm. Monica Stoudemire's stepped into the Chief Compliance Officer's shoes with a track record that'd make any investor breathe a sigh of relief. After all, blending two decades of on-the-ground experience with regulatory acumen ain't...

RTI's $14M Boost: A Game-Changer for Tech Innovators

Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...

K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...

Flex Dental Solutions Adds BNPL, Surcharging to FlexPayments

Diving into Dental Finances: A New Moneymaker? It's about time someone shook up the dental payment scene, and Flex Dental Solutions seems to be the one doing it. They rolled out some intriguing new features for their FlexPayments platform aimed squarely at dental practices using Open Dental. What we're seeing here is their attempt to bridge a couple of financial headaches...

Moore Law Investigates Aardvark Therapeutics' Risks

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...

AbbVie's Bold Leap in Menstrual Migraine Treatment

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

Helio Fred Garcia Honored by Diversity Action Alliance

Award Ceremony Set in the Big Apple In an industry where recognition often feels as transient as a ticker's daily high, the Diversity Action Alliance (DAA) is doing its bit to emphasize the lasting impact individuals can make. On September 16 in New York City, Helio Fred Garcia will be honored with the 2026 Pat Ford Larger Than Life Impact Award at the DAA's Annual...

Unpacking RAGEism: Power Dynamics in U.S. Policies

Seeing Patterns in Crisis: Jackson and Flint When Jackson, Mississippi's latest water crisis hit the news, it wasn't the first time folks were left high and dry. No, this fiasco's got deep roots, and it resonates with another infamous case: Flint, Michigan. In Maya Rockeymoore Cummings' book, RAGEism, these are badge-worthy examples of 'Resource Hoarding' where government...

Atli Launches: AI-Powered eSIM Revolutionizes Travel

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

SES Sells to AFC Industries: A Strategic M&A Move

Nashville's Notable Deal in Industrial Supply On a muggy September day in Nashville, XLCS Partners announced it was at the helm of a noteworthy transaction—the sale of Signature Engineered Solutions (SES) to AFC Industries. Now, this isn't just another corporate shuffle; it's a calculated move in the gritty world of fastening and engineered solutions. The Nitty-Gritty...